—

Fairmount Funds Management LLC

Q1 2026 13F Holdings

  • Location
    west conshohocken, PA
  • Num holdings

    12

  • Value ($000)

    $1,384,339

  • Date Filed
    05/15/2026
  • Form type
    13F-HR
  • CIK
    0001802528
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q1 2026 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
---

DAMORA THERAPEUTICS INC

COM NEW
36322Q206
$225.67M
16 %

8,713,000

D
DNTH

DIANTHUS THERAPEUTICS INC

COM
252828108
$212.92M
15 %

2,537,191

C
COGT

COGENT BIOSCIENCES INC

COM
19240Q201
$211.83M
15 %

5,503,418

S
SYRE

SPYRE THERAPEUTICS INC

COM NEW
00773J202
$202.67M
15 %

4,018,101

---

ORUKA THERAPEUTICS INC

COM
687604108
$181.74M
13 %

3,705,262

V
VRDN

VIRIDIAN THERAPEUTICS INC

COM
92790C104
$76.57M
6 %

3,914,458

E
ELVN

ENLIVEN THERAPEUTICS INC

COM
29337E102
$72.74M
5 %

1,855,644

---

JADE BIOSCIENCES INC

COM NEW
008064206
$63.98M
5 %

4,553,494

---

CRESCENT BIOPHARMA INC.

COM
G2545C104
$50.48M
4 %

2,747,866

---

ZENAS BIOPHARMA INC

COM
98937L105
$46.12M
3 %

2,359,025

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 12